Cancer drug resistance: an evolving paradigm

Caitriona Holohan, Sandra Van Schaeybroeck, Daniel B Longley, Patrick G Johnston

Research output: Contribution to journalArticlepeer-review

3304 Citations (Scopus)


Resistance to chemotherapy and molecularly targeted therapies is a major problem facing current cancer research. The mechanisms of resistance to 'classical' cytotoxic chemotherapeutics and to therapies that are designed to be selective for specific molecular targets share many features, such as alterations in the drug target, activation of prosurvival pathways and ineffective induction of cell death. With the increasing arsenal of anticancer agents, improving preclinical models and the advent of powerful high-throughput screening techniques, there are now unprecedented opportunities to understand and overcome drug resistance through the clinical assessment of rational therapeutic drug combinations and the use of predictive biomarkers to enable patient stratification.
Original languageEnglish
Pages (from-to)714-26
JournalNature Reviews. Cancer
Issue number10
Early online date24 Sept 2013
Publication statusPublished - Oct 2013

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Cancer drug resistance: an evolving paradigm'. Together they form a unique fingerprint.

Cite this